Aldo Peixoto, MD
Professor of Medicine (Nephrology)Cards
About
Research
Overview
Medical Subject Headings (MeSH)
Academic Achievements and Community Involvement
Clinical Care
Overview
Aldo Peixoto, MD, is the chief of nephrology at Yale Medicine. He specializes in resistant and secondary forms of hypertension, cardiovascular dysautonomia (an autonomic nervous system disorder) and in general consultative nephrology and hypertension.
Dr. Peixoto received his medical degree from the Federal University of Santa Catarina in Brazil in 1992. He was a medical resident and chief medical resident at the University of Connecticut Health Center from 1992 to 1996 and later completed a nephrology fellowship at Yale University. In 1998, he joined Yale Medicine as a full-time faculty member.
As a clinician, Dr. Peixoto believes in letting his patients share in the decision-making process. “It’s not about what I want the patient to do. It’s about what the two of us can agree on that is important for the patient and then moving forward as a team,” he says. In order to accomplish this, Dr. Peixoto tries to understand patients’ preferences early on—whether it’s certain types of medication or if their lifestyle prevents them from accessing certain treatments. This type of information is particularly important in diseases where there is not enough scientific research to make a strong recommendation and there is some flexibility in treatment options, says Dr. Peixoto.
In addition to seeing patients, Dr. Peixoto conducts research on how blood pressure, the vascular system, and kidney disease affect each other. At the Yale School of Medicine, he is a professor of medicine (nephrology).
Clinical Specialties
Fact Sheets
Polycystic Kidney Disease (PKD)
Learn More on Yale MedicineAcute Kidney Injury (AKI)
Learn More on Yale MedicineDiagnosing Kidney Disease
Learn More on Yale MedicineHigh Blood Pressure (Hypertension)
Learn More on Yale Medicine
Board Certifications
Nephrology
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2008
- Original Certification Date
- 1998
Internal Medicine
- Certification Organization
- AB of Internal Medicine
- Latest Certification Date
- 2008
- Original Certification Date
- 1995
Yale Medicine News
Links & Media
Media
- Critical steps in the evaluation and management of acute severe hypertension. There is very limited evidence guiding the management of hypertensive urgencies, so many of the recommendations are based on expert opinion. (Peixoto. N Engl J Med 2019: 381(19):1843-1852. doi: 10.1056/NEJMcp1901117.
- Clonidine is a go-to drug in patients with acute severe hypertension without acute target organ injury. Previous data suggested that its "smoother" pattern of BP decline made it a useful drug. In this study, we challenge this concept, as up to 16% of patients had excessive BP reductions (>30%) and 7% had significant adverse events within 24h, mostly acute kidney injury. (Hanna, Ghazi, Yamamoto, Simonov, Shah, Wilson and Peixoto. Am J Hypertension 2022: doi: 10.1093/ajh/hpac004. Online ahead of print.)
- The approach to the differential diagnosis of orthostatic hypotension starts with an analysis of the appropriateness of the heart rate response. This key step guides all further decision on diagnosis and treatment. (Peixoto. Clev Clin J Med 2022: 89 (1) 36-45; DOI: https://doi.org/10.3949/ccjm.89gr.22001)
News
- March 25, 2024Source: Leadership Currency with Dr. Doug McKinley
Leading From the Middle
- March 11, 2024
Understanding Spontaneous Blood Pressure Reduction in Severe Hypertension
- September 20, 2022
Quality & Safety Process Improvement Project Funding Fall 2022
- December 20, 2021
Announcing Quality Improvement Grant Winners (Fall 2021)